This inhibitory activity reduces the expression of NF-κB–induced cytokines and growth factors that regulate multiple myeloma cells and also pre-osteoclasts, resulting in less bone destruction [165–167]. This evidence concerns the gene NFKB1 and plasma cell myeloma.